Ekaterina Dmitrievna Savina

Ms. Ekaterina Dmitrievna Savina


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in Marine Drugs
Verified
Journal Article
Open access
PDF file
EZEkaterina Zhidkova
Ekaterina Zhidkova
ESEkaterina Dmitrievna Savina
Ekaterina Dmitrievna Savina
Ekaterina YurchenkoEkaterina Yurchenko
Ekaterina Yurchenko
ELEkaterina Lesovaya
Ekaterina Lesovaya
Steroids, particularly glucocorticoids, are essential components of cancer treatment for both hematological malignancies and solid tumors. The adverse effects of standard steroid-based drugs have forced drug discovery research to develop chemotherapeutics with a more selective mechanism of action and an improved therapeutic index. Steroids of natural origin and their analogs are a significant source of novel molecules with a wide spectrum of biological activities. In this review, we aimed to analyze marine-derived steroids and their anti-cancer activity. Moreover, we specifically discussed molecules with not only anti-cancer but also anti-inflammatory activities that could potentially mimic the effects of glucocorticoids. We hypothesized that several of the reviewed compounds could exhibit affinity to the glucocorticoid receptor, and possess the properties of selective glucocorticoid receptor agonists/modulators with increased therapeutic activity and decreased side effects. The review is based on the literature available in the PubMed, Cochrane, and ClinicalTrials.gov databases and covers the period from 1986 to 2025. The keywords used were “steroids”, “cancer”, and “marine-derived steroids”. The second iteration of the literature search included the keywords “selective glucocorticoid receptor agonists”, “marine-derived”, and “cancer”. In silico calculations of several marine-derived compounds were performed to support the hypothesis based on the literature data.

24 December 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
EZEkaterina Zhidkova
Ekaterina Zhidkova
EOEvgenia Oleynik
Evgenia Oleynik
EMEkaterina A. Mikhina
Ekaterina A. Mikhina
DSDaria Stepanycheva
Daria Stepanycheva
DGDiana Grigoreva
Diana Grigoreva
ELEkaterina Lesovaya
Ekaterina Lesovaya
Glucocorticoids (GCs) are routinely used to treat hematological malignancies; however, long-term treatment with GCs can lead to atrophic and metabolic adverse effects. Selective glucocorticoid receptor agonists (SEGRAs) with reduced side effects may act as a superior alternative to GCs. More than 30 SEGRAs have been described so far, yet none of them reached clinical trials for anti-cancer treatment. In the present work, we propose a novel approach to increase the number of potential SEGRAs by obtaining derivatives of synephrine, a molecule of natural origin. We synthesized 26 novel compounds from the class of synephrine derivatives and characterized them by HRMS, and 1H and 13C NMR. We evaluated in vitro anti-cancer effects in leukemia K562 and lymphoma Granta cells using the MTT assay and studied their potential affinity for the glucocorticoid receptor (GR) in silico using the molecular docking approach. The novel derivative 1-[4-(benzyloxy)phenyl]-2-(hexylamino)ethanol (10S-E2) with the highest GR affinity in silico exhibited cytotoxic activity against K562 and Granta cells after 24 h of treatment at the concentration of approximately 13 µM which correlated with its highest MolDock Score. The other compound with high GR affinity, 2-(hexylamino)-1-(4-nitrophenyl)ethanol (13S-G2), demonstrated cytotoxicity in both cell lines at concentrations of 50–70 µM. Overall, our results may provide a solid rationale for developing and further investigating synephrine derivatives as SEGRAs with anti-cancer activity.

18 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EZEkaterina Zhidkova
Ekaterina Zhidkova
EOEvgenia Oleynik
Evgenia Oleynik
EMEkaterina A. Mikhina
Ekaterina A. Mikhina
DSDaria Stepanycheva
Daria Stepanycheva
DGDiana Grigoreva
Diana Grigoreva
ELEkaterina Lesovaya
Ekaterina Lesovaya
Glucocorticoids (GC) are widely used in the treatment of hematological malignancies; however, the long-term treatment lead to atrophic and metabolic adverse effects. Selective glucocorticoid receptor agonists (SEGRA) with reduced side effects could be the better GC alternative. More than 30 SEGRA were described but none of them reached clinical trials as anticancer treatment. In the present work, we proposed the novel approach to broaden the list of potential SEGRA by synthesis of derivatives of synephrine, the molecule of natural origin. We synthesized 26 compounds from the class of synephrine derivatives, and studied their anticancer effect in vitro in leukemia and lymphoma cells with MTT assay as well as their potential affinity to glucocorticoid receptor (GR) in silico using molecular docking approach. Novel derivative 1-[4-(benzyloxy)phenyl]-2-(hexylamino)ethanol (10S-E2) with the highest GR affinity in silico revealed the micromolar range cytotoxicity in lymphoma and leukemia cells after 24 h of treatment. The other compound, 2-(hexylamino)-1-(4-nitrophenyl)ethanol (13S-G2) with high GR affinity demonstrated cytotoxicity in the range of 50-70 µM. Overall, our results provide the rationale for the development and further investigation of synephrine derivatives as SEGRA with anticancer activity.

18 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EZEkaterina Zhidkova
Ekaterina Zhidkova
ESEkaterina Dmitrievna Savina
Ekaterina Dmitrievna Savina
Ekaterina YurchenkoEkaterina Yurchenko
Ekaterina Yurchenko
ELEkaterina Lesovaya
Ekaterina Lesovaya
Steroids, particularly glucocorticoids, are essential components of cancer treatment for both hematological malignancies and solid cancers. The adverse effects of standard steroid-based drugs have forced drug discovery research to develop chemotherapeutics with a more selective mechanism of action and, therefore, an improved therapeutic index. Steroids of natural origin and their analogs represent a significant source of novel molecules with a wide spectrum of biological activities. In the presented review, we aimed to analyze marine-derived steroids and their anticancer activity. Moreover, we discussed more specifically the molecules with not only anti-cancer but also anti-inflammatory activities that could potentially mimic the effects of glucocorticoids. We hypothesized that several of the reviewed compounds could reveal the affinity to glucocorticoid receptor, and, furthermore, could possess the properties of selective glucocorticoid receptor agonists/modulators with increased therapeutic activity and decreased side effects.

24 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EZEkaterina Zhidkova
Ekaterina Zhidkova
ESEkaterina Dmitrievna Savina
Ekaterina Dmitrievna Savina
DSDaria Stepanycheva
Daria Stepanycheva
OVOlga Aleksandrovna Vlasova
Olga Aleksandrovna Vlasova
TVTimur Valiev
Timur Valiev
ELEkaterina Lesovaya
Ekaterina Lesovaya
Background/Objectives: Glucocorticoids (GCs) present effective anti-cancer drugs for the treatment of hematological malignancies but their clinical use is limited due to their multiple adverse effects. Selective glucocorticoid receptor agonists/modulators (SEGRAMs) modify glucocorticoid receptor (GR) function shifting it towards therapeutically important transrepression and, therefore, could be safer alternative to GCs. Here we report on biological activity of four novel ligands of glucocorticoid receptor (GR), derivatives of natural origin molecule, synephrine. Methods: We demonstrated the affinity of synephrine derivatives in silico and in vitro by molecular dynamics simulation and radioligand binding assay, correspondingly. Further, we tested the induction of apoptosis in cultured cells and cytotoxic effects in primary lymphoblasts from the patients with acute lymphoblastic leukemia. Therapeutically important GR transrepression was evaluated by luciferase reporter assay and Q-PCR of transrepression marker genes, while GR transactivation associated with side effects was evaluated by Q-PCR analysis and by the level of GR phosphorylation at Ser211. Anti-cancer effects of leader compound, 1-[4-(benzyloxy)phenyl]-2-(hexylamino)ethanol (10S-E2), was studied on murine transplantable lymphoma P388 model. 10S-E2 potential to avoid the development of atrophic complication was evaluated on the murine model of glucocorticoid-induced osteoporosis. Results: All studied synephrine derivatives demonstrated high GR affinity; the effects on GR function were controversial. The leader compound, 10S-E2 revealed SEGRAM properties in vitro and demonstrated anti-cancer effects in vivo. Conclusion: Although the anti-cancer effect of 10S-E2 was less pronounced to the reference drug dexamethasone, non-atrophogenic properties of 10S-E2 make this molecule an attractive candidate for long-term GR-associated therapies.

Verified
Journal Article
Open access
PDF file
EZEkaterina Zhidkova
Ekaterina Zhidkova
ESEkaterina Dmitrievna Savina
Ekaterina Dmitrievna Savina
DSDaria Stepanycheva
Daria Stepanycheva
OVOlga Aleksandrovna Vlasova
Olga Aleksandrovna Vlasova
TVTimur Valiev
Timur Valiev
ELEkaterina Lesovaya
Ekaterina Lesovaya
Glucocorticoids (GCs) represent effective anti-cancer drugs for the treatment of hematological malignancies, but their clinical use is limited due to their multiple adverse effects. Selective glucocorticoid receptor agonists/modulators (SEGRAMs) modify glucocorticoid receptor (GR) function, shifting it towards therapeutically important transrepression and, therefore, could be safer alternative to GCs. Here we report on the biological activity of four novel glucocorticoid receptor (GR) ligands, derivatives of synephrine, a natural-origin molecule. We demonstrated the affinity of synephrine derivatives in silico and in vitro by molecular dynamics simulation and radioligand binding assay, correspondingly. Further, we tested the induction of apoptosis in cultured cells and cytotoxic effects in primary lymphoblasts from patients with acute lymphoblastic leukemia. Therapeutically important GR transrepression was evaluated by luciferase reporter assay and Q-PCR of transrepression marker genes, while GR transactivation associated with side effects was evaluated by Q-PCR analysis and by the level of GR phosphorylation at Ser211. Anti-cancer effects of the leader compound, 1-[4-(benzyloxy)phenyl]-2-(hexylamino)ethanol (10S-E2), were studied using a murine transplantable lymphoma P388 model. The potential of 10S-E2 to prevent the development of atrophic complication was evaluated using a murine model of glucocorticoid-induced osteoporosis. All studied synephrine derivatives demonstrated high GR affinity, with the IC50 value of the most active derivative 10S-E2 being 0.56 µM; the effects on GR function were cell-type-specific. The leader compound, 10S-E2, revealed SEGRAM properties in vitro and demonstrated anti-cancer effects in vivo, inhibiting tumor growth by more than 60%. Although the anti-cancer effect of 10S-E2 was less pronounced than that of the reference drug dexamethasone, non-atrophogenic properties of 10S-E2 make this molecule an attractive candidate for long-term GR-associated therapies.